• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    Asia Pacific Lancet Pen Needels Market

    ID: MRFR/MED/0187-HCR
    90 Pages
    Kinjoll Dey
    October 2025

    Lancet and Pen Needles Market Research Report, By Therapy (Insulin, (GLP-1), Growth Hormones), Gauge (17/18G, 21G, 23G), Needle Length (4mm, 8mm, 12mm), And End Users (Medical Institutions & Research Organizations) – The Asia Pacific Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Asia Pacific Lancet Pen Needels Market Infographic
    Purchase Options

    Asia Pacific Lancet Pen Needels Market Summary

    The Asia-Pacific Lancet and Pen Needles market is projected to grow significantly from 1.95 USD Billion in 2024 to 4.93 USD Billion by 2035.

    Key Market Trends & Highlights

    Asia Pacific Lancet and Pen Needles Key Trends and Highlights

    • The market is expected to expand at a compound annual growth rate (CAGR) of 8.81% from 2025 to 2035.
    • By 2035, the market value is anticipated to reach 4.93 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 1.95 USD Billion, laying a strong foundation for future expansion.
    • Growing adoption of advanced pen needle technology due to increasing prevalence of diabetes is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.95 (USD Billion)
    2035 Market Size 4.93 (USD Billion)
    CAGR (2025-2035) 8.81%

    Major Players

    BD. (U.S.), Novo Nordisk A/S (Europe), Ypsomed (Europe), B. Braun Melsungen AG (Europe), HTL-STREFA (Europe), Terumo Corporation (Asia Pacific), Artsana S.p.A. (Europe), Owen Mumford Ltd. (Europe)

    Key Companies in the Asia Pacific Lancet Pen Needels Market market include

    Industry Developments

    February 2024: Eli Lilly hopes to launch its bestselling antidiabetic medication, specified as Mounjaro (tripeptide), which will be around early next year. Indian health regulatory bodies, including Mounjaro, are currently investigating this.

    According to Minister Mykhailo Fedorov for Digital Transformation in Ukraine, contracts will be signed first about the mass production of attack drones similar to Russian Lancet drones in February 2024. Among them is the kamikaze drone Lancet manufactured by ZALA Aero Group, which has a range of forty kilometers and belongs to Kalashnikov Concern’s large enterprise division, Russian Armaments Manufacturer.

    June 2023: Shilpa Biologicals Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited (SML), was granted marketing authorization for its Adalimumab injection in prefilled syringe (PFS). It is a biosimilar for high concentration adalimumab formulation for rheumatoid arthritis treatment.

    During CPHI Japan 2023, SHL Medical introduced Molly modular platform autoinjectors with pre-installed Needle Isolation Technology (NIT).

    September 2022: The Microsoft and Novo Nordisk partnership was announced in September 2022, merging computational services, cloud computing AI and knowledge thirst in drug development as well as Novo Nordisk’s data engineering services.

    On September 2022, Novo Nordisk acquired Forma Therapeutics. That company is committed to changing lives of Sickle cell disease (SCD) patients among other rare blood diseases.

    Market Segmentation

    Intended Audience

    • Pharmaceutical companies
    • Biotechnological institutes
    • Government and Private Laboratories
    • Research and Development (R&D) Companies
    • Medical Research Laboratories
    • Market Research and Consulting Service Providers 

    Asia Pacific Lancet and Pen Needles Market Overview

    • Pharmaceutical companies
    • Biotechnological institutes
    • Government and Private Laboratories
    • Research and Development (R&D) Companies
    • Medical Research Laboratories
    • Market Research and Consulting Service Providers 

    Key Players for Asia Pacific Lancet and Pen Needles Market

    • BD. (U.S.)
    • Novo Nordisk A/S (Europe)
    • Ypsomed (Europe)
    • B. Braun Melsungen AG (Europe)
    • HTL-STREFA (Europe)
    • Terumo Corporation (Asia Pacific)
    • Artsana S.p.A. (Europe)
    • Owen Mumford Ltd. (Europe)

    Report Scope

    Attribute/Metric Details
    Market Size 2030  USD 3.45 Billion 2032
    Compound Annual Growth Rate (CAGR) 12.67% 2032
    Base Year 2021
    Market Forecast Period 2024-2032
    Historical Data 2018 - 2021
    Market Forecast Units Value (USD Million)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, technology, application, and end-users.
    Geographies Covered Americas, Europe, Asia Pacific and the Middle East and Africa
    Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
    Key Companies Profiled BD. (U.S.), Novo Nordisk A/S (Europe), Ypsomed (Europe), B. Braun Melsungen AG (Europe), HTL-STREFA (Europe), Terumo Corporation (Asia Pacific), Artsana S.p.A. (Europe), Owen Mumford Ltd. (Europe).
    Key Market Opportunities Key market opportunities in the Asia Pacific lancet and pen needles market include rising diabetes prevalence, increasing healthcare expenditure, and growing awareness about advanced diabetes management technologies.
    Key Market Dynamics The key market dynamics for the Asia Pacific lancet and pen needles market include rising diabetes prevalence, increasing adoption of self-monitoring blood glucose devices, technological advancements in needle design, growing awareness and patient education, and expanding healthcare infrastructure.

    Market Highlights

    Author
    Kinjoll Dey
    Research Analyst Level I

    He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

    Leave a Comment
    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials